Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis.
CXCL9
PD-L1
PD1
prognosis
stage T1 NMIBC
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Sep 2020
29 Sep 2020
Historique:
received:
03
09
2020
revised:
23
09
2020
accepted:
24
09
2020
entrez:
2
10
2020
pubmed:
3
10
2020
medline:
3
10
2020
Statut:
epublish
Résumé
Non-muscle invasive bladder cancer (NMIBC), which is characterized by a recurrence rate of approximately 30% and very long treatment times, remains a major unresolved problem for patients and the health care system. The immunological interplay between tumor cells and the immune environment is important for tumor development. Therefore, we analyzed the mRNA of three immune markers,
Identifiants
pubmed: 33003392
pii: cancers12102794
doi: 10.3390/cancers12102794
pmc: PMC7601021
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : ELAN Fund
ID : ELAN 18-08-18-1-Sikic
Organisme : Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of the Friedrich-Alexander University Erlangen-Nuremberg
ID : none
Organisme : Rudolf und Irmgard Kleinknecht-Stiftung
ID : none
Organisme : Johannes und Frieda Marohn-Stiftung
ID : none
Organisme : Wilhelm Sander-Stiftung
ID : Förderantrag Nr. 2015.171.1
Références
Oman Med J. 2020 Mar 11;35(2):e103
pubmed: 32181005
Front Oncol. 2020 Jul 22;10:1197
pubmed: 32775303
Cancers (Basel). 2020 Jan 24;12(2):
pubmed: 31991604
Eur Urol. 2013 Feb;63(2):234-41
pubmed: 22877502
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Oncotarget. 2017 Oct 13;8(59):100614-100630
pubmed: 29246006
J Immunother Cancer. 2020 May;8(1):
pubmed: 32448798
Genomics. 1994 Oct;23(3):704-6
pubmed: 7851902
Cancer Immunol Immunother. 2018 Mar;67(3):403-412
pubmed: 29150702
Bladder Cancer. 2016 Jan 7;2(1):37-47
pubmed: 27376123
Transl Oncol. 2017 Jun;10(3):340-345
pubmed: 28342317
Expert Rev Anticancer Ther. 2018 Jul;18(7):695-703
pubmed: 29737231
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
Cancer Immunol Res. 2019 Jun;7(6):923-938
pubmed: 30988029
Curr Opin Urol. 2018 Nov;28(6):598-603
pubmed: 30138123
Urology. 2008 Jan;71(1):131-5
pubmed: 18242381
Oncotarget. 2018 Sep 25;9(75):34066-34078
pubmed: 30344922
Urol Oncol. 2020 May;38(5):476-487
pubmed: 32192892
Cancers (Basel). 2020 May 15;12(5):
pubmed: 32429318
Biochem Biophys Res Commun. 1993 Apr 15;192(1):223-30
pubmed: 8476424
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
BMC Cancer. 2019 Nov 6;19(1):1054
pubmed: 31694589
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Eur Urol. 2009 Sep;56(3):430-42
pubmed: 19576682
Anticancer Agents Med Chem. 2013 Nov;13(9):1391-405
pubmed: 24102276
Front Immunol. 2016 Dec 12;7:550
pubmed: 28018338
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Virchows Arch. 2017 Mar;470(3):267-274
pubmed: 28074276
J Urol. 2004 Jul;172(1):70-5
pubmed: 15201740
Urol Int. 2016;96(2):136-41
pubmed: 26789626
Urol Oncol. 2017 May;35(5):257-263
pubmed: 28291636
Nat Med. 1999 Dec;5(12):1365-9
pubmed: 10581077
Urol Oncol. 2017 Sep;35(9):576-577
pubmed: 28789929
Immunology. 2008 Jul;124(3):419-27
pubmed: 18217952
Oncol Rep. 2015 Jun;33(6):3075-84
pubmed: 25963805
Int J Cancer. 1983 Jan 15;31(1):13-20
pubmed: 6339421
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3110-5
pubmed: 24520177
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
BJU Int. 2008 Aug;102(3):270-5
pubmed: 18494831
Cytogenet Cell Genet. 1996;74(4):255-8
pubmed: 8976378